Microbot Medical Inc. MBOT
Description of Business.
is a medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices
targeting the minimally invasive surgery space. We are primarily focused on leveraging our robotic technologies with the goal of redefining
surgical robotics while improving surgical outcomes for patients.
Last close
1.44
2026-09-04
Market cap
$96.7M
2026-06-30 share count
52-week range
1.44 - 4.25
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.29
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $6.3M | $6.6M | $5.7M | $7.7M | $6.2M | $3.4M | $3.0M | $2.5M | $1.1M | -$901.0K |
| SG&A | $8.5M | $5.0M | $4.1M | $5.5M | $5.2M | $5.7M | $4.2M | $4.7M | $4.2M | -$8.7M |
| Total operating expenses | — | — | — | $4.6M | $3.9M | — | — | — | — | — |
| Operating income | -$14.7M | -$11.6M | -$9.9M | -$13.3M | -$11.4M | -$9.1M | -$7.2M | -$7.2M | $5.3M | -$9.6M |
| Interest expense | — | — | — | — | — | — | — | $2.0K | $237.0K | $333.0K |
| Pre-tax income | — | — | — | — | — | -$9.2M | -$7.2M | — | — | — |
| Income tax | — | — | — | — | — | $0 | $0 | — | — | — |
| Net income | -$13.1M | -$11.4M | -$10.7M | -$13.2M | -$11.3M | -$9.2M | -$7.2M | -$7.3M | -$7.6M | -$9.7M |
| EPS, basic | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 | — | — | — | — | — |
| EPS, diluted | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 | -1.29 | -1.70 | -2.41 | -2.76 | 0.40 |
| Shares, diluted (wtd. avg.) | 45.8M | 15.6M | 10.2M | 7.3M | 7.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.9M | $3.1M | $2.5M | $2.4M | $13.5M | $19.6M | $28.8M | $5.2M | $10.8M | $2.7M |
| Short-term investments | $74.7M | $2.4M | $3.9M | $5.8M | $2.0M | $5.0M | $2.5M | — | — | — |
| Inventory | $584.0K | — | — | — | — | — | — | — | — | — |
| Total current assets | $79.8M | $5.8M | $7.9M | $8.8M | $15.9M | $25.3M | $35.9M | $5.8M | $10.9M | $3.3M |
| Property, plant and equipment | $93.0K | $80.0K | $146.0K | $221.0K | $244.0K | $251.0K | $228.0K | $259.0K | $90.0K | $53.0K |
| Total assets | $81.5M | $6.0M | $8.3M | $9.5M | $16.8M | $26.3M | $37.1M | $6.1M | $11.0M | $3.4M |
| Accounts payable | $511.0K | $165.0K | — | $116.0K | $279.0K | $275.0K | $284.0K | $630.0K | $78.0K | $512.0K |
| Total current liabilities | $3.4M | $2.5M | $3.8M | $2.1M | $2.0M | $1.3M | $4.8M | $4.8M | $528.0K | $783.0K |
| Total liabilities | $4.0M | $2.5M | $3.8M | $2.2M | $2.4M | $2.0M | $5.6M | $4.8M | $556.0K | $1.2M |
| Retained earnings | -$104.1M | -$90.9M | -$79.5M | -$68.8M | -$55.6M | -$44.3M | -$35.1M | -$27.9M | -$20.6M | -$13.0M |
| Total equity | $77.6M | $3.5M | $4.5M | $7.3M | $14.4M | $24.3M | $31.5M | $1.3M | $10.0M | $1.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.0M | -$8.8M | -$8.5M | -$11.5M | -$9.4M | -$7.3M | -$6.5M | -$5.3M | -$4.9M | -$786.0K |
| Depreciation and amortisation | $47.0K | $91.0K | $106.0K | $102.0K | $76.0K | $68.0K | $84.0K | $54.0K | $21.0K | $10.0K |
| Stock-based compensation | $1.1M | $1.3M | $1.4M | $1.8M | $1.4M | $1.9M | $1.1M | $1.4M | $479.0K | $676.0K |
| Capital expenditure | $60.0K | $25.0K | $33.0K | $84.0K | $69.0K | $91.0K | $216.0K | $223.0K | $58.0K | $25.0K |
| Investing cash flow | -$72.4M | $1.5M | $2.0M | -$3.8M | $3.2M | -$2.8M | -$2.5M | -$223.0K | -$58.0K | -$25.0K |
| Financing cash flow | $86.2M | $7.9M | $6.6M | $4.3M | — | -$3.4M | $36.8M | -$18.0K | $13.0M | $3.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012935.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$9.7M | -$7.6M | -$7.3M | -$7.2M | -$9.2M | -$11.3M | -$13.2M | -$10.7M | -$11.4M | -$13.1M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |